ULS_10.2-MED-Conferências
URI permanente para esta coleção:
Navegar
Entradas recentes
- Report of a rare 3q29 interstitial microdeletion: prenatal diagnosis and postnatal follow-upPublication . Simão, Laurentino; Pedro, Sónia; Marques, Bárbara; Serafim, Sílvia; Ferreira, Cristina; Tarelho, Ana; Brito, Filomena; Silva, Marisa; Alves, Cristina; Viegas, Mónica; Silva, Ana Paula; Rodrigues, Márcia; Ferreira, Ângela; Correia, HildebertoDistal interstitial deletions in the 3q29 region are rare. The characterization of new prenatal diagnosis (PND) cases and their follow-up may add knowledge about the affected region.
- Is preoperative chemosensitivity associated with improved outcomes in locally advanced gastric cancer? A multicentric retrospective real-world studyPublication . Caleça, T.; Honório, M.; Sousa, M.; Ribeiro, J.; Fortuna, A.; Silva, D. Neto da; Albuquerque, J.; Menezes, M.; Trabulo, C.; Costa, D.Perioperative chemotherapy (PCT) is the standard of care for locally advanced gastric cancer (LAGC) in western countries. However, less than 60% of patients complete the adjuvant part of treatment due to postoperative complications, toxicity and disease progression (DP). This study aim is to evaluate if preoperative chemosensitivity (POCS) is associated with improved overall survival (OS) and disease free survival (DFS).
- Nephrotic syndrome in pregnant diabetic women: maternal and perinatal outcomes at a tertiary centerPublication . Nogueira, Estela; Afonso, Rita; Godinho, Iolanda; Centeno, Mónica; Pinto, Luísa; Lopes, José AntónioManagement of pregnant women with diabetic kidney disease and nephrotic range proteinuria or nephrotic syndrome constitute a challenge to clinicians. Maternal and perinatal outcomes, especially in patients with chronic kidney disease, remain poor. The authors describe the multidisciplinary approach and the outcomes of diabetic pregnant patients with nephrotic range proteinuria.
- Adalimumab and number of previous biological disease-modifying antirheumatic drugs as predictive factors for the development of immune-mediated skin lesionsPublication . Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.Treatment of inflammatory rheumatic diseases has dramatically changed with the introduction of biologic disease modifying anti-rheumatic drugs (bDMARDs). However, these drugs aren’t exempt from risks and skin lesions are the most frequent adverse reactions. Among the possible adverse skin reactions, immune-mediated skin lesions (IMSL) may occur. Risk factors associated with the occurrence of IMSL in rheumatic patients under bDMARDs are poorly known and studied.
- Immune-mediated skin lesions related to biological disease-modifying antirheumatic drugs: a 22-year experience of a tertiary centerPublication . Martins, A.; Oliveira, D. Santos; Martins, F. R.; Nicolau, R.; Pinheiro, F. Oliveira; Rato, M.; Bernardo, A.; Pimenta, S.; Bernardes, M.; Costa, L.Biological disease-modifying antirheumatic drugs (bDMARDs) have revolutionized the treatment of chronic inflammatory rheumatic diseases. However, the physician and the patient should be aware of possible adverse reactions. Skin is one of the most frequent organs involved in bDMARD adverse reactions and immune-mediated skin lesions (IMSL) have rarely been described before in cohort studies and their incidence is unknown.
- Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are not predictive of pathologic complete response to neoadjuvant chemotherapy in triple-negative breast cancerPublication . Pinho, I. Soares de; Barroso, T.; Trabulo, C.; Campoa, E.; Patel, V.; Gonçalves, L.; Araújo, J.; Monteiro, C.; Ferreira, A.; Machado, B.; Dâmaso, S.; Luz, P.; Sousa, R. Teixeira de; Costa, L.Pathological complete response (pCR) to neoadjuvant chemotherapy (NAChT) has been validated as a predictor of long-term survival in breast cancer (BC), especially in triple-negative breast cancer (TNBC)
- Maintaining remission after an episode of steroid-responsive acute severe ulcerative colitis: what is the best strategy?Publication . Bravo, C.; Gomes, C. Frias; Blesl, A.; Damasceno, J.; Drygiannakis, I.; Argyriou, K.; Festa, S.; Aratari, A.; Todeschini, A.; Jelakovic, M.; Kani, H. Tarik; Idrees, Z.; Feijó, D.; Chaves, C.; Bacsur, P.; Michalopoulos, G.; Turcan, S.; Nardone, O. M.; Spyridon, V.; Bernardi, A. De; Nagmeldin, I.; Denjagic, M. Basic; Ribaldone, D. Giuseppe; Ploutarchos, P.; Karakan, T.; Oliveira, R.; Balestrieri, P.; Lopes, S.; Vasilakis, T.; Taelman, T.; Neri, B.; Clarke, M.; Mocci, G.; Kiudelis, G.; Vieujean, S.; Sciberras, N.; Milenkovic, Z.; Bonazzi, E.; Karmiris, K.; Torres, J.The best maintenance therapy after a steroid-responsive acute severe ulcerative colitis (ASUC) episode remains poorly studied and is not addressed in current guidelines. We aimed to compare the impact of different treatment strategies following hospitalization for steroid-responsive ASUC.
- Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort studyPublication . Noviello, D.; Chaparro, M.; Viganò, C.; Blesl, A.; Barberio, B.; Yanai, H.; Macaluso, F.; Iglesias, R. Ferreiro; Bezzio, C.; Zilli, A.; Molnár, T.; Gheorghe, C.; Conforti, F. S.; Innocenti, T.; Saibeni, S.; Bossuyt, P.; Oliveira, R. F. de; Gabrielli, A. M. Carvalhas; Losco, A.; Vieujean, S.; Tettoni, E.; Pirola, L.; Calderone, S.; Cohen, M. Kornowski; Dragoni, G.; Rath, T.; Acosta, M. Barreiro-de; Savarino, E. V.; Gisbert, J. P.; Vecchi, M.; Atreya, R.; Caprioli, F.Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited. We aimed to assess the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large retrospective multicenter cohort study
- Clinical profile and treatment outcomes in patients receiving advanced therapies for ulcerative colitis – the READ-UC real-world studyPublication . Fernandes, S. R.; Sousa, H. Tavares de; Portela, F.; Ministro, P.; Lago, P.; Branquinho, D.; Freitas, I.; Machado, N. Martins; Magro, F.Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that requires effective treatment with the main goal of inducing and maintaining remission. This study aimed to characterize UC patients receiving advanced therapies (AT), by describing their demographic and clinical characteristics and remission outcomes.
- Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel DiseasePublication . Oliveira, R.; Roseira, J.; Araújo, N.; Cavaco, C.; André, J.; Sousa, M.; Sousa, H. Tavares de; Cunha, M.We aimed to compare real-life direct and indirect costs and the environmental impact of switching IBD patients from IV to SC infliximab (IFX).